Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASHKAN ABBEY

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1548402886
CMS profile
161327
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$92,609.05

138 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Alimera Sciences, Inc. $24,904.65 26
Regeneron Healthcare Solutions, Inc. $15,787.56 24
ABBVIE INC. $14,323.13 27
Genentech USA, Inc. $14,106.48 17
Biogen, Inc. $7,983.08 7
Alcon Research LLC $5,415.00 6
Apellis Pharmaceuticals, Inc. $5,181.38 9
EyePoint Pharmaceuticals US, Inc. $3,037.28 9
Bausch & Lomb Americas Inc. $1,652.83 8
Genentech, Inc. $120.85 1
Alcon Vision LLC $38.86 2
Coherus Biosciences Inc. $34.77 1
VYERA PHARMACEUTICALS, LLC $23.18 1

Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASHKAN ABBEY

NPI 1548402886 · CMS profile ID 161327

Allopathic & Osteopathic Physicians / Ophthalmology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548402886?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASHKAN ABBEY, NPI 1548402886, CMS profile ID 161327. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548402886?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ASHKAN ABBEY, NPI 1548402886, CMS profile ID 161327. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548402886?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ASHKAN ABBEY, NPI 1548402886, CMS profile ID 161327, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1548402886?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

138 matching records · $92,609.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 138 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–138 of 138.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alimera Sciences, Inc. $19.6106/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896605245 CMS
Regeneron Healthcare Solutions, Inc. $103.8006/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927094785 CMS
Alimera Sciences, Inc. $35.6806/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896603821 CMS
EyePoint Pharmaceuticals US, Inc. $24.4206/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932989431 CMS
Alcon Research LLC $1,140.0006/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920372357 CMS
Alimera Sciences, Inc. $80.5906/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929751497 CMS
Alimera Sciences, Inc. $249.9606/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929751505 CMS
Alimera Sciences, Inc. $5,000.0006/02/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929751493 CMS
Genentech USA, Inc. $22.9206/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950776667 CMS
ABBVIE INC. $15.6205/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890447033 CMS
Apellis Pharmaceuticals, Inc. $107.3305/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964255113 CMS
EyePoint Pharmaceuticals US, Inc. $149.9304/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932989695 CMS
ABBVIE INC. $26.6504/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890447031 CMS
Regeneron Healthcare Solutions, Inc. $249.9604/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927094783 CMS
Regeneron Healthcare Solutions, Inc. $27.1504/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927094781 CMS
Alimera Sciences, Inc. $23.1604/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896605205 CMS
Bausch & Lomb Americas Inc. $28.6504/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957460977 CMS
ABBVIE INC. $650.0004/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890447029 CMS
VYERA PHARMACEUTICALS, LLC $23.1804/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937568507 CMS
Regeneron Healthcare Solutions, Inc. $14.6604/01/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927094779 CMS
Alimera Sciences, Inc. $117.1303/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929751489 CMS
EyePoint Pharmaceuticals US, Inc. $85.0503/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932989683 CMS
EyePoint Pharmaceuticals US, Inc. $52.3203/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932989699 CMS
ABBVIE INC. $25.7303/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890447027 CMS
Alimera Sciences, Inc. $8,000.0003/16/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929751485 CMS
Alimera Sciences, Inc. $19.6603/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896605221 CMS
Genentech USA, Inc. $149.9403/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950787993 CMS
ABBVIE INC. $22.6202/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890447025 CMS
Genentech USA, Inc. $17.4302/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950801027 CMS
Alcon Vision LLC $20.6202/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935082037 CMS
EyePoint Pharmaceuticals US, Inc. $22.5602/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932990703 CMS
Alcon Vision LLC $18.2402/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905087529 CMS
Genentech USA, Inc. $780.0002/10/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950681471 CMS
Bausch & Lomb Americas Inc. $24.4102/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957460997 CMS
ABBVIE INC. $24.9901/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890447023 CMS
Regeneron Healthcare Solutions, Inc. $35.3101/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927094777 CMS
Regeneron Healthcare Solutions, Inc. $1.5801/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927094775 CMS
Alimera Sciences, Inc. $22.0101/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896605209 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $65,540.75 107
PY2020 $39,460.14 40
PY2021 $50,631.06 88
PY2022 $92,609.05 138
PY2023 $151,112.01 167
PY2024 $86,653.29 133
PY2025 $73,404.52 109

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $14,735.65 3
PY2025 Principal investigator $1,051,062.70 141
PY2024 Recipient $77,990.23 16
PY2024 Principal investigator $558,687.89 68
PY2023 Principal investigator $663,687.98 38
PY2022 Principal investigator $831,052.16 52
PY2021 Principal investigator $794,526.53 39
PY2020 Principal investigator $636,290.71 28
PY2019 Principal investigator $622,417.60 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

144 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 12/31/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776251
Principal investigator 1 Ocular Therapeutix, Inc. $2,700.00 12/15/2025 Non-covered Recipient Entity
Texas Retina Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240093
Principal investigator 1 Ocular Therapeutix, Inc. $24,620.40 12/12/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240137
Principal investigator 1 SANOFI US SERVICES INC. $28,740.40 12/12/2025 Non-covered Recipient Entity
Texas Retina Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226088191
Principal investigator 1 Genentech, Inc. $2,734.00 12/11/2025 Non-covered Recipient Entity
Texas Retina Associates
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211663657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,289.54 12/11/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,330.44 12/11/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,330.44 12/11/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273623
Principal investigator 1 Apellis Pharmaceuticals, Inc. $32,909.00 12/03/2025 Non-covered Recipient Entity
Texas Retina Associates
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250364221
Principal investigator 1 SANOFI US SERVICES INC. $2,649.40 12/01/2025 Non-covered Recipient Entity
Southeast Retina Center, Pc
Age-related macular degeneration No dispute reported 06/30/2026 1226107679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,029.93 11/27/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184265969
Principal investigator 1 Genentech, Inc. $5,500.00 11/21/2025 Non-covered Recipient Entity
Texas Retina Associates
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211663661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $905.38 11/19/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262577
Principal investigator 1 Hoffmann-La Roche Limited $42,249.00 11/12/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211663695
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,684.00 11/07/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364199
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,684.00 11/07/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364201
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,684.00 11/07/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364203
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,684.00 11/07/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364205
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,684.00 11/07/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364207
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 11/07/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364209
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 11/07/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364211
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 11/07/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364213
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 11/07/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364215
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 11/07/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364217
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 11/07/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364219
Principal investigator 1 Genentech, Inc. $26,640.00 11/05/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211663684
Principal investigator 1 SANOFI US SERVICES INC. $10,207.60 11/03/2025 Non-covered Recipient Entity
Austin Clinical Research, Llc
Age-related macular degeneration No dispute reported 06/30/2026 1226100230
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 10/31/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,330.44 10/29/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,330.44 10/29/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255223
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 10/28/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,497.49 10/17/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251389
Principal investigator 1 SANOFI US SERVICES INC. $61,928.10 10/17/2025 Non-covered Recipient Entity
Texas Retina Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226101719
Principal investigator 1 ABBVIE INC. $260,700.00 10/16/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
IIT-2018-10566//The Use of a Combination of Ozurdex and Eylea versus Eylea Monotherapy for Diabetic Macular Edema: A Prospective, Comparative Trial (COED Trial) No dispute reported 06/30/2026 1202517175
Principal investigator 1 Ocular Therapeutix, Inc. $2,520.00 10/15/2025 Non-covered Recipient Entity
Texas Retina Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240091
Principal investigator 1 ABBVIE INC. $5,041.54 10/14/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202516751
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/13/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,330.44 10/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,922.72 10/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,330.44 10/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,922.72 10/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246574
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,922.72 10/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,922.72 10/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,330.44 10/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,330.44 10/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246582
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,922.72 10/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246584
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,330.44 10/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246586
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 09/30/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776245
Principal investigator 1 Genentech, Inc. $29,801.00 09/26/2025 Non-covered Recipient Entity
Texas Retina Associates
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211663642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 09/24/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 09/24/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 09/24/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,922.72 09/24/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,185.46 09/11/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184236041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,184.84 09/11/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184236043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,132.06 09/11/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184236045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,293.00 09/10/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,062.00 09/10/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235699
Principal investigator 1 SANOFI US SERVICES INC. $14,416.35 09/05/2025 Non-covered Recipient Entity
Texas Retina Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226088180
Principal investigator 1 Ocular Therapeutix, Inc. $57.91 09/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240121
Principal investigator 1 Ocular Therapeutix, Inc. $43,874.10 09/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240123
Principal investigator 1 ABBVIE INC. $16,341.42 09/02/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202507057
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 08/29/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776243
Principal investigator 1 ABBVIE INC. $5,883.94 08/27/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506181
Principal investigator 1 Genentech, Inc. $8,074.00 08/22/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211663676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 08/06/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 08/06/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 08/06/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 08/06/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 08/06/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 08/06/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223750
Principal investigator 1 Genentech, Inc. $2,300.00 08/01/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211663681
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 07/31/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776241
Recipient Regeneron Pharmaceuticals, Inc. $3,407.50 07/31/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184114857
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,684.00 07/16/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364173
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 07/16/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 07/16/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,897.31 07/16/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,897.31 07/16/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216416
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,897.31 07/16/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216418
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,897.31 07/16/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,897.31 07/16/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216422
Principal investigator 1 SANOFI US SERVICES INC. $40,249.95 07/11/2025 Non-covered Recipient Entity
Texas Retina Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226088175
Principal investigator 1 Janssen Research & Development, LLC $4,115.00 07/04/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175403750
Principal investigator 1 Hoffmann-La Roche Limited $8,995.00 07/01/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211663687
Principal investigator 1 Hoffmann-La Roche Limited $2,500.00 07/01/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211663692
Recipient Ocular Therapeutix, Inc. $10,879.35 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 06/30/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184212185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 06/30/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184212187
Principal investigator 1 Genentech, Inc. $15,850.00 06/25/2025 Non-covered Recipient Entity
Texas Retina Associates
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211663604
Principal investigator 1 Genentech, Inc. $5,002.00 06/25/2025 Non-covered Recipient Entity
Texas Retina Associates
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211663614
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 06/24/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776229
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 06/24/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776231
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 06/24/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776233
Principal investigator 1 Boehringer Ingelheim International GmbH $43.70 06/24/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776235
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,110.00 06/20/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364191
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,223.00 06/20/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364193
Principal investigator 1 SANOFI US SERVICES INC. $2,700.00 06/04/2025 Non-covered Recipient Entity
Texas Retina Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226088149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 06/02/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 06/02/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 06/02/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 06/02/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 06/02/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,897.31 06/02/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,000.00 05/28/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199663
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,110.00 05/16/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364195
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,684.00 05/16/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364197
Principal investigator 1 ANI Pharmaceuticals, Inc. $23,843.75 05/15/2025 Non-covered Recipient Entity
Texas Retina Associates 47
New Day Study No dispute reported 06/30/2026 1248567393
Principal investigator 1 ANI Pharmaceuticals, Inc. $3,271.13 05/15/2025 Non-covered Recipient Entity
Texas Retina Associates 47
New Day Study No dispute reported 06/30/2026 1248567405
Principal investigator 1 Ocular Therapeutix, Inc. $7,100.00 05/14/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240103
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,744.31 05/02/2025 Non-covered Recipient Entity
RETINA FOUNDATION OF THE SOUTHWEST
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study No dispute reported 06/30/2026 1190310460
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 04/30/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776237
Principal investigator 1 Boehringer Ingelheim International GmbH $95.01 04/30/2025 Non-covered Recipient Entity
Texas Retina Associates Dallas-Main
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220776239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 04/23/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 04/23/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 04/23/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 04/23/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,416.66 04/23/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 04/23/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,416.66 04/23/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 04/23/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,305.03 04/23/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188607
Principal investigator 1 SANOFI US SERVICES INC. $11,857.95 04/23/2025 Non-covered Recipient Entity
Texas Retina Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226088136
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,223.00 04/16/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364189
Recipient Regeneron Pharmaceuticals, Inc. $448.80 04/16/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184114855
Principal investigator 1 Genentech, Inc. $13,144.00 04/11/2025 Non-covered Recipient Entity
Texas Retina Associates
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211663619
Principal investigator 1 Janssen Research & Development, LLC $1,472.00 03/31/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175403743
Principal investigator 1 Genentech, Inc. $19,630.00 03/26/2025 Non-covered Recipient Entity
Texas Retina Associates
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211663623
Principal investigator 1 SANOFI US SERVICES INC. $1,752.50 03/26/2025 Non-covered Recipient Entity
Texas Retina Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226088317
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,684.00 03/14/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364185
Principal investigator 1 SANOFI US SERVICES INC. $8,237.00 03/14/2025 Non-covered Recipient Entity
Texas Retina Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226088076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,416.66 03/12/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,416.66 03/12/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,416.66 03/12/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172540
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,416.66 03/12/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172572
Principal investigator 1 Janssen Research & Development, LLC $4,115.00 03/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175403739
Principal investigator 1 Janssen Research & Development, LLC $629.00 03/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175403757
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 02/19/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364177
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 02/19/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364179
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 02/19/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364181
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 02/19/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364183
Principal investigator 1 Janssen Research & Development, LLC $3,931.00 02/03/2025 Non-covered Recipient Entity
TEXAS RETINA ASSOCIATES
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175403733
Principal investigator 1 ANI Pharmaceuticals, Inc. $500.00 01/30/2025 Non-covered Recipient Entity
Texas Retina Associates 47
New Day Study No dispute reported 06/30/2026 1248567627
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,495.00 01/24/2025 Non-covered Recipient Entity
Texas Retina Associates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364187